ClinicalTrials.gg
CompletedNCT02641899Updated Jan 27, 2017

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

A Phase 1 interventional study of ITCA 650 20/60 mcg/day and Acetaminophen in Healthy, sponsored by Intarcia Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-27.

Sponsored by Intarcia Therapeutics · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A Phase 1, Fixed-Sequence, Open-label Study in Healthy Subjects to Estimate the Effects of ITCA 650 on Gastric Emptying and on the Absorption Pharmacokinetics of Each of 4 Commonly Studied DDI Probe Compounds.

Read the detailed description

Acetaminophen will be use to assess the effect of ITCA 650 on the rate of gastric emptying.

Interactions between ITCA 650 and the medications lisinopril, digoxin, atorvastatin, and warfarin will also be studied.

02

Conditions studied

  • Healthy

Keywords

  • Adult
  • Male
  • Female
  • Volunteers
03

In context

Lead sponsor

Intarcia Therapeutics is the lead sponsor of 21 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 19 to 32 kg/m2.
  • Glycosylated (HbA1c )\<6.5%.
  • Normal renal function ( ≥80 mL/min/1.73 m2).
  • Women of child bearing potential - use of an additional adequate method of during the study and until 1 additional menstrual cycle following the end-of-study (EOS) visit. Adequate methods of contraception for women of child bearing potential () include: mechanical products (ie, intrauterine device [IUD]-copper IUD); or barrier methods (eg, diaphragm, condoms, cervical cap) with spermicide.

Exclusion criteria

Exclusion Criteria:

  • History of type 1 or type 2 diabetes.
  • History or evidence of myocardial infarction, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular accident or stroke.
  • History of uncontrolled hypertension.
  • History or evidence of acute or chronic pancreatitis.
  • History of liver disease.
  • History of medullary thyroid cancer or a personal or family history of multiple endocrine neoplasia type 2.
  • Poor thyroid, liver, or renal function.
  • Weight loss surgery or requires weight loss medications.
  • History of (not including basal or squamous cell carcinoma of the skin with past 5 years). (Subjects who have been disease free for 5 years may be included.)
  • History of active alcohol or substance abuse.
  • Weekly consumption of more than 7 alcoholic beverages for females and 14 alcoholic beverages for males.
  • Excessive in xanthine consumption (more than 5 cups of coffee or equivalent per day).
  • Treatment with medications that affect GI motility.
  • Any condition that would affect drug transit time or absorption (eg, gastrointestinal bypass surgery, partial or total gastrectomy, small bowel resection, chronic diarrhea, vagotomy, chronic gastroesophageal reflux disease, malabsorption, colostomy, Crohn's disease, ulcerative colitis, or celiac sprue).
  • History of to exenatide.
  • or warnings according to the specific label(s) for acetaminophen, atorvastatin, lisinopril, digoxin or warfarin therapy.
  • Women that are pregnant, lactating, or planning to become pregnant.
  • Concurrent use of anticoagulants, including daily low dose aspirin (81 mg).
  • History of or positive results on screening tests for and/or and/or (HIV).
  • Planned in-patient surgery, dental procedure, or hospitalization during the study.
  • Prior or current treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist (eg, Bydureon™, Byetta®, Victoza®, Tanzeum® or exogenous native GLP-1) or prior participation in an ITCA 650 clinical trial.
  • Use or intended use of any drug or other product that inhibits or induces cytochrome P450 (CYP)1A2, CYP2C9, CYP2C19, or within 14 days prior to the first dose of warfarin or ITCA650 or during the conduct of the study.
  • History of thrombophlebitis, thromboembolic disorders, or deep vein thrombophlebitis.
  • Fasting triglycerides above at Screening.
  • Any gastrointestinal complaints within 7 days prior to first dosing.
  • Taking drugs or natural herbal supplements (such as albuterol, antacids, and St. John's Wort) with known interactions with atorvastatin, lisinopril, digoxin, or warfarin from within 7 days prior to Day 1 until EOS
  • Consumed or unwilling to refrain from grapefruit, cranberries, grapefruit- or cranberry-containing products, or Seville oranges from within 7 days prior to Day 1 until EOS.
  • Chronic use of analgesics, pain medication, or non-steroidal anti-inflammatory agents.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Experimental Treatment

    ITCA 650 20/60 mcg/day Acetaminophen 1000 mg Atorvastatin 40 mg Lisinopril 20 mg Warfarin 25 mg Digoxin 0.5 mg

    Drug: ITCA 650 20/60 mcg/day · Drug: Acetaminophen · Drug: Atorvastatin · Drug: Lisinopril · Drug: Warfarin · Drug: Digoxin

Interventions

  • DrugITCA 650 20/60 mcg/day

    ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.

  • Oral acetaminophen 1000 mg on Day 1 and Day 27

  • Oral atorvastatin 40 mg on Day 2 and Day 28

  • Oral lisinopril 20 mg on Day 2 and Day 28

  • DrugWarfarin

    Oral warfarin 25 mg on Day 2 and Day 28

  • DrugDigoxin

    Oral digoxin 0.5 mg on Day 2 and Day 28

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from time zero to the last measurable concentration [AUC(0-last)]) of acetaminophen alone and in the presence of ITCA 650.

    Time frame: time zero to 10 weeks

  2. Maximum plasma concentration ([Cmax]) of acetaminophen alone and in the presence of ITCA 650

    Time frame: time zero to 10 weeks

  3. Area under the concentration-time curve (AUC(0-last)) of atorvastatin, lisinopril, digoxin, R-warfarin, and S-warfarin each alone and in the presence of ITCA 650.

    Time frame: time zero to 10 weeks

  4. Cmax of atorvastatin, lisinopril, digoxin, R-warfarin, and S-warfarin each alone and in the presence of ITCA 650.

    Time frame: time zero to 10 weeks

Secondary outcomes

  1. Time to maximum plasma concentration (tmax) of acetaminophen

    Time frame: time zero to 10 weeks

  2. tmax of atorvastatin, lisinopril, digoxin, R warfarin, and S-warfarin

    Time frame: time zero to 10 weeks

  3. AUC(0-last) of orthohydroxy-atorvastatin and parahydroxy-atorvastatin

    Time frame: time zero to 10 weeks

  4. Cmax of orthohydroxy-atorvastatin and parahydroxy-atorvastatin

    Time frame: time zero to 10 weeks

  5. Maximum effect (Emax)from time zero to the last measurable concentration (AUEC(0-last)) of international normalized ratio (INR) of warfarin.

    Time frame: time zero to 10 weeks

  6. Cmax of ITCA 650, 20 mcg/d and 60 mcg/d

    Time frame: within 8 hours after placement of ITCA 650

  7. Treatment-emergent adverse events (TEAEs) including any events local to the placement site, clinical laboratory measurements, ECGs, vital signs and physical examinations.

    Time frame: time zero to 10 weeks

  8. Tmax of orthohydroxy-atorvastatin and parahydroxy-atorvastatin

    Time frame: time zero to 10 weeks

  9. Cmin of ITCA 650, 20 mcg/d and 60 mcg/d

    Time frame: time zero to 10 weeks

  10. Tmax of ITCA 650, 20 mcg/d and 60 mcg/d

    Time frame: time zero to 10 weeks

  11. Tmin of ITCA 650, 20 mcg/d and 60 mcg/d

    Time frame: zero to 10 weeks

  12. Time of maximum effect (tEmax)from time zero to the last measurable concentration (AUEC(0-last)) of international normalized ratio (INR) of warfarin.

    Time frame: zero to 10 weeks

  13. Area under the effect-time curve from time zero to the last measurable concentration (AUEC(0-last)) of international normalized ratio (INR) of warfarin.

    Time frame: zero to 10 weeks

07

Study locations

1 site
  • Quintiles
    Overland Park, Kansas 66211, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2015
First posted
Dec 30, 2015
Start
Dec 2015
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Last update
Jan 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02641899
Responsible party
Sponsor
First posted
Dec 30, 2015
Start date
Dec 2015
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Jan 27, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetaminophen · Atorvastatin · Lisinopril

Start the discussion